Triple-negative breast cancer accounts for approximately 20% of breast cancer cases worldwide. Its hallmark is the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This receptor-negative status precludes the use of hormonal or HER2-targeted treatments, severely limiting therapeutic options. Clinically, TNBC disproportionately affects younger women, exhibits rapid metastatic potential, and is burdened by a high rate of early recurrence and mortality. These aggressive characteristics have positioned TNBC as a critical challenge in oncology.

Given the lack of conventional molecular targets in TNBC, research efforts have expanded beyond the malignant cells to encompass their surrounding environment. The tumour microenvironment comprises a dynamic consortium of connective tissue, immune cells, fibroblasts, extracellular matrix components, and vasculature. This environment can paradoxically either impede or foster tumorigenesis, suggesting that its molecular interplay may hold keys to combating the disease.

In an innovative study published in Current Drug Therapy, a multidisciplinary team at the HSE Faculty of Biology and Biotechnology dissected the gene expression profiles of both TNBC tumour cells and their microenvironment components. By correlating these molecular data with extensive patient clinical records, they identified critical regulatory pathways influencing tumour aggressiveness and patient outcomes. Central to their discovery is the insulin-like growth factor 2 (IGF2), a well-known signalling protein implicated in tissue growth and repair, but hijacked in cancer to fuel unregulated proliferation.

Contrary to conventional assumptions that the tumour cells produce the essential growth-supporting factors, this study found that fibroblasts—connective tissue cells resident within the tumour microenvironment—are the predominant source of IGF2 in TNBC. These fibroblasts, normally maintaining tissue architecture and homeostasis, seem to switch roles under the pathological state, becoming facilitators of cancer progression by secreting IGF2, effectively “fueling the fire” of tumour expansion.

Adjacent to this growth-promoting mechanism, the tumour possesses an intrinsic regulatory system aimed at tempering unchecked development. This restraint is mediated by the insulin-like growth factor binding protein 6 (IGFBP6), a molecular “trap” that binds IGF2, preventing it from excessive activation of tumour cells. Intriguingly, the researchers observed that both tumour and microenvironmental cells produce IGFBP6 as a counterbalance to growth stimuli, suggesting a finely tuned equilibrium under normal conditions.

The study’s clinical analysis revealed a troubling link between diminished IGFBP6 expression and heightened infiltration of macrophages within tumours. Macrophages, pivotal immune cells tasked with host defense, can undergo functional reprogramming in cancer to adopt tumor-supportive roles. This reprogramming fosters a pro-tumoral milieu, promoting angiogenesis, matrix remodeling, and immune suppression, factors collectively contributing to accelerated disease recurrence and poor prognosis in affected patients.

These findings carry immediate translational significance. Measuring IGFBP6 levels in tumour biopsies could serve as a prognostic biomarker, enabling clinicians to stratify patients by recurrence risk more accurately. High-risk individuals with low IGFBP6 expression and macrophage-enriched tumours might benefit from intensified surveillance and tailored therapeutic regimens, potentially improving survival outcomes.

Looking forward, the elucidation of this tumour microenvironment axis opens exciting prospects for the development of novel treatments. Current chemotherapeutic strategies targeting rapidly dividing cancer cells often fall short against TNBC’s resilience. Redirecting therapeutic focus to the supportive fibroblasts and immune components within the microenvironment offers a promising paradigm shift. For instance, elevating IGFBP6 levels pharmacologically or inhibiting IGF2 production in fibroblasts could undermine the tumour’s growth advantage, effectively “starving” cancer cells of their supportive niche.

Maxim Shkurnikov, leading the research at HSE’s Laboratory for Research on Molecular Mechanisms of Longevity, emphasizes this strategic reorientation: “Conventional chemotherapy primarily targets rapidly dividing cells, and in triple-negative breast cancer this is often insufficient. We propose shifting the focus to the tumour microenvironment and targeting the cells that support tumour growth. By modulating IGFBP6 and IGF2 dynamics, we hope to develop therapies that significantly reduce the risk of rapid recurrence.”

This research underscores the critical importance of the tumour microenvironment in dictating cancer progression and recurrence, particularly in TNBC, where options remain limited. It aligns with a growing body of evidence suggesting that addressing not only the malignant cells but also the surrounding stromal and immune components is essential for durable therapeutic success.

Moreover, this discovery may have implications beyond TNBC, offering insights into other malignancies where the IGF axis and immune microenvironment interplay governs tumour behavior. The identification of biomarkers like IGFBP6 and the delineation of fibroblast-derived IGF2 in cancer progression herald a new wave of personalized oncology approaches grounded in microenvironmental biology.

In summary, the HSE University study marks a significant advance in cancer biology, highlighting that the aggressive nature of triple-negative breast cancer is not solely an intrinsic feature of tumour cells but critically influenced by their microenvironment. By targeting these auxiliary cells and their molecular signals, there lies an opportunity to outmaneuver this formidable disease and improve outcomes for patients currently facing limited options.

Subject of Research: Molecular mechanisms and tumour microenvironment in triple-negative breast cancer

Article Title: IGFBP6 Expression Correlates with Macrophage Presence in Triple-Negative Breast Cancer Tumors

News Publication Date: 2 January 2026

Web References:
https://doi.org/10.2174/0115748855416908251120055038

References:
HSE University research team, Current Drug Therapy, 2026

Keywords:
Triple-negative breast cancer, tumour microenvironment, IGF2, IGFBP6, fibroblasts, macrophages, cancer recurrence, molecular oncology, tumour progression, targeted therapy, immune cells, cancer biomarkers

Breast ductal carcinoma is one of the most prevalent forms of cancer, with millions affected worldwide. Understanding the dynamics of the tumor microenvironment is critical because it encompasses not just the tumor cells but also a variety of non-cellular components such as extracellular matrix, soluble factors, and immune cells. The interplay between these elements can determine how effectively the body combats the cancerous growth. This research sheds light on the intricate relationships within this microenvironment, highlighting how they evolve as the disease progresses.

The study employs advanced imaging and histological techniques to visualize the tumor microenvironment in breast ductal carcinoma. Cheng and colleagues utilized sophisticated imaging methods that allow for a detailed view of the spatial arrangement of cellular components within the tumor. This not only provides clarity about where different cell types reside but also about how their interactions may foster or inhibit tumor growth. This innovative approach overcomes many traditional limitations faced in cancer research, providing a more holistic view of tumor biology.

Additionally, the research identifies specific patterns of malignant epithelial transitions as cancer progresses. The team analyzed how tumor cells differentiate and invade surrounding tissues, which is crucial in understanding metastasis—the spread of cancer to other parts of the body. It becomes evident that the microenvironment is not a passive background but an active participant in cancer progression. The study brings to light the role of various signaling pathways and cellular interactions that facilitate these transitions.

These findings could pave the way for new therapeutic targets. By illustrating how the microenvironment influences malignant behavior, this research opens avenues for developing therapies that disrupt these interactions. For instance, if specific signaling pathways can be inhibited or modulated, it may be possible to slow or halt the progression of the cancer. This could lead to more effective treatments that not only target the cancer cells themselves but also modify the supporting environment to make it less conducive to tumor growth.

Moreover, the research emphasizes the need for personalized medicine in treating breast ductal carcinoma. The variability in tumor microenvironments between patients suggests that a one-size-fits-all approach to treatment may not be effective. By understanding individual tumor microenvironments, oncologists could tailor treatments that are specifically designed to target the unique features of a patient’s cancer.

The study also discusses the potential implications of these findings for predicting patient outcomes. Understanding the spatial and temporal aspects of tumor progression could help in developing prognostic tools that take the intricacies of the tumor microenvironment into account. This would enable better risk stratification for patients and inform treatment decisions based on the aggressiveness of their cancer.

Furthermore, the implications for clinical practice cannot be understated. Integrating insights from this research into routine diagnostics could enhance the way clinicians approach breast ductal carcinoma. It challenges the traditional views of cancer treatment and underscores the importance of seeing tumors as part of a larger ecosystem that includes the surrounding microenvironment.

In addition to providing crucial insights into breast ductal carcinoma, this study also highlights the interdisciplinary nature of modern cancer research. The collaboration between biologists, chemists, and clinicians exemplifies the need to integrate various scientific disciplines in order to tackle complex diseases. It encourages a holistic approach to cancer research and treatment that may yield greater benefits for patients.

As these findings circulate within the scientific community, they may influence future research directions. The study invites further exploration into other types of cancers where similar microenvironmental dynamics may be at play. Continued research could validate these findings across various cancer types, enriching our collective understanding of cancer biology and therapy.

Finally, the potential for this study to influence public health initiatives cannot be overlooked. By emphasizing the importance of early detection and personalized medicine, it could inspire programs aimed at increasing awareness of breast cancer and its biological complexities. As researchers continue to decode the mysteries of cancer, findings such as these serve as vital stepping stones in the quest for more effective treatments and, ultimately, a cure.

In conclusion, the research led by Cheng, X., Zeng, W., and Yin, B. on the spatiotemporal microenvironment landscape in breast ductal carcinoma progression is a significant contribution to the field of oncology. By bridging the gap between basic research and clinical application, it lays the groundwork for future breakthroughs in cancer treatment strategies, offering hope for improved patient outcomes in the battle against one of the leading causes of cancer-related deaths worldwide.

Subject of Research: Breast ductal carcinoma and its spatiotemporal microenvironment.

Article Title: Spatiotemporal microenvironment landscape and malignant epithelial pattern transition in breast ductal carcinoma progression.

Article References:

Cheng, X., Zeng, W., Yin, B. et al. Spatiotemporal microenvironment landscape and malignant epithelial pattern transition in breast ductal carcinoma progression. J Transl Med 23, 996 (2025). https://doi.org/10.1186/s12967-025-07010-3

Image Credits: AI Generated

DOI:

Keywords: Breast cancer, ductal carcinoma, tumor microenvironment, epithelial transitions, cancer progression, personalized medicine.